Genfit (NASDAQ:GNFT) Stock Price Down 2.8% – Time to Sell?

Genfit S.A. (NASDAQ:GNFT) was down 2.8% during mid-day trading on Monday . The stock traded as low as $3.50 and last traded at $3.53. Approximately 4,533 shares traded hands during mid-day trading, a decline of 66% from the average daily volume of 13,269 shares. The stock had previously closed at $3.63.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $13.00 price target on shares of Genfit in a research report on Friday, February 7th.

Genfit Stock Down 2.8 %

The company has a debt-to-equity ratio of 0.61, a current ratio of 3.74 and a quick ratio of 3.74. The stock has a fifty day moving average price of $3.69 and a two-hundred day moving average price of $4.32.

Institutional Trading of Genfit

An institutional investor recently bought a new position in Genfit stock. Millennium Management LLC purchased a new position in shares of Genfit S.A. (NASDAQ:GNFT) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm purchased 166,375 shares of the company’s stock, valued at approximately $611,000. Millennium Management LLC owned about 0.33% of Genfit at the end of the most recent reporting period. 2.24% of the stock is owned by hedge funds and other institutional investors.

About Genfit

Genfit SA, a late-stage biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company develops Elafibranor, which is in Phase III clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; VS-01 for the treatment of Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is in Phase 1b/2a trial to treat patients with cholangiocarcinoma (CCA); VS-01-ACLF and Nitazoxanide (NTZ), which is in Phase 1 trial to treat acute-on-chronic liver failure, as well as VS-02-HE, which is in preclinical trial for the treatment of Reduction of Hyperammonemia and the Stabilization of Blood Ammonia; CML-022; SRT-015, an ASK1 inhibitor targets the inhibition of cellular apoptosis, inflammation, and fibrosis.